Based on various reports, the common timing for initiation or resumption of LHRHa therapy in PCa patients with distant metastasis was defined variably as follows: PSA level of at least 10 ng/mL; PSA level of at least 10 ng/mL with symptoms; or PSA level of at least 20 ng/mL. This evidence concerns the gene KLK3 and posterior cortical atrophy.